HRS video: ALTITUDE assesses survival after shock therapy

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Click to play
HRS Video: Brian D. Powell, MD
ALTITUDE Principal Investigator
Mayo Clinic
Rochester, Minn.

SAN FRANCISCO—The ALTITUDE study, presented as a late-breaking clinical trial at this year’s annual Heart Rhythm Society (HRS) meeting, evaluated the survival rates of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy-defibrillator (CRT-D) recipients after shock therapy.

The trial conveyed surprising results, including that atrial fibrillation patients saw an increased rate of mortality.

Brian D. Powell, MD, a cardiologist from the Mayo Clinic in Rochester, Minn., and principal investigator of the study sat down with Cardiovascular Business to discuss the trial’s impacts and results, as well as how to optimize follow-up for these device patients.